Ardelyx (MEX:ARDX) Notes Receivable: MXN0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:ARDX Ardelyx Inc MEX:ARDX
66 GF Score
Price MXN99.00
GF Value MXN212.14
! 5 Warning Signs
View Full Analysis

What is Ardelyx Notes Receivable?

Ardelyx MEX:ARDX 66 Notes Receivable is MXN0 Mil as of Jun. 2026. GuruFocus rates MEX:ARDX with a GF Score™ of 66/100 and a GF Value™ of MXN212.14. The stock has 5 warning signs investors should review.

Ardelyx's Notes Receivable for the quarter that ended in Jun. 2026 was MXN0 Mil.

Ardelyx Notes Receivable Historical Data

* Premium members only.

The historical data trend for Ardelyx's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ardelyx Notes Receivable Chart

Ardelyx Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Ardelyx Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MEX:ARDX
66GF Score
Ardelyx Inc MEX:ARDX
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ardelyx Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of MXN0 Mil mean?
Ardelyx (MEX:ARDX) has a Notes Receivable of MXN0 Mil as of Jun. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Ardelyx and its competitors.
Is Ardelyx's Notes Receivable too high?
Ardelyx's current Notes Receivable is MXN0 Mil. Overall, Ardelyx has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does Ardelyx's Notes Receivable compare to IMTX and TRAX?
Ardelyx's Notes Receivable of MXN0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Ardelyx and its competitors. Ardelyx's current Notes Receivable is MXN0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ardelyx stock overvalued right now?
Ardelyx (MEX:ARDX) has a current Notes Receivable of MXN0 Mil. The stock's GF Value™ is MXN212.14, compared to a current price of MXN99.00 — trading 53.3% below its estimated fair value. The current Notes Receivable is MXN0 Mil. Ardelyx's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Ardelyx (MEX:ARDX), the current Notes Receivable is MXN0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ardelyx (MEX:ARDX) Overvalued in 2026?

Based on GuruFocus' analysis, Ardelyx stock appears to be undervalued. The current stock price of MXN99.00 is trading 53.3% below its estimated GF Value™ of MXN212.14.

Key valuation signals for MEX:ARDX:

  • Notes Receivable: MXN0 Mil
  • GF Value™: MXN212.14 vs. price of MXN99.00 (53.3% below fair value)
  • GF Score™: 66/100 with 5 warning signs

No single metric tells the full story. See the MEX:ARDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ardelyx Business Description

Other Exchanges ARDX:USA41X:Germany
Address 400 Fifth Avenue, Suite 210, Waltham, MA, USA, 02451
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
66GF Score

Get the complete analysis for MEX:ARDX

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN99.00
Price
MXN212.14
GF Value